



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.
INVENTION: : IG LAMBDA BIOPOLYMER MARKERS
PREDICTIVE OF ALZHEIMERS DISEASE
SERIAL NUMBER : 09/991,797
FILING DATE : November 23, 2001
EXAMINER: : (not assigned yet)
GROUP ART UNIT : 1632
ATTORNEY DOCKET NO. : 2132.084

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 8-16-02
Susan Weiss

Box Sequence
U.S. Patent & Trademark Office
P.O. Box 2327
Arlington, VA 22202

Sir:

Please find enclosed for filing:

- X Response to Notice to Comply With Requirements
- X Computer Readable Form Sequence Listing (paper copy 2 sheets)
- X Computer Readable Form Sequence Listing (diskette).
- X Copy of Notice to File Missing Parts

Respectfully submitted,

Date: 8/16/2002

By: Ferris H. Lander
Ferris H. Lander
Registration No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/991,797	11/23/2001	George Jackowski	2132.084

CONFIRMATION NO. 5616


FORMALITIES LETTER



OC000000008596978

Michael A. Slavin, Esq.
McHale & Slavin, P.A.
Suite 402
4440 PGA Boulevard
Palm Beach Gardens, FL 33410

Date Mailed: 08/08/2002



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE